Emricasan: Phase I data

Data from 15 healthy volunteers in a Phase I trial showed that exposure to 25 mg emricasan given as a single dose or twice daily for 10 days in combination with cyclosporine did not interfere with physiologically normal levels of apoptosis or pro-apoptotic caspase activity. Data were presented at the American Association for the Study of Liver Diseases meeting in Washington, D.C. The company previously reported that emricasan rapidly suppresses apoptotic caspase activity in HCV patients as measured by caspase-cleaved CK18 levels to within ranges typically reported for healthy volunteers. ...